Your browser doesn't support javascript.
loading
Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.
Cotton, Jennifer L; Estrada Diez, Javier; Sagar, Vivek; Chen, Julie; Piquet, Michelle; Alford, John; Song, Youngchul; Li, Xiaoyan; Riester, Markus; DiMare, Matthew T; Schumacher, Katja; Boulay, Gaylor; Sprouffske, Kathleen; Fan, Lin; Burks, Tyler; Mansur, Leandra; Wagner, Joel; Bhang, Hyo-Eun C; Iartchouk, Oleg; Reece-Hoyes, John; Morris, Erick J; Hammerman, Peter S; Ruddy, David A; Korn, Joshua M; Engelman, Jeffrey A; Niederst, Matthew J.
Afiliação
  • Cotton JL; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Estrada Diez J; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Sagar V; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Chen J; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Piquet M; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Alford J; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Song Y; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Li X; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Riester M; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • DiMare MT; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Schumacher K; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Boulay G; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Sprouffske K; Oncology Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Fan L; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Burks T; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Mansur L; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Wagner J; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Bhang HC; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Iartchouk O; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Reece-Hoyes J; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Morris EJ; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Hammerman PS; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Ruddy DA; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Korn JM; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Engelman JA; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Niederst MJ; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Cancer Res ; 83(21): 3611-3623, 2023 11 01.
Article em En | MEDLINE | ID: mdl-37603596

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article